Promising Pathway Act

12/30/2022, 5:32 PM

Promising Pathway Act

This bill establishes a provisional approval pathway for medicines intended for serious or life-threatening diseases, including illnesses posing a threat of epidemic or pandemic. The period of the provisional approval is for two years and is potentially renewable.

The Food and Drug Administration (FDA) must establish a priority review system to evaluate completed provisional approval applications within 90 days of receipt. A provisional approval application may be approved if the FDA determines that (1) there is substantial evidence of safety for the drug; and (2) there is relevant early evidence of efficacy, based on adequate and well-controlled investigations.

During the COVID-19 (i.e., coronavirus disease 2019) pandemic, or another epidemic or pandemic, the FDA must accept and review various portions of a provisional approval application on a rolling basis.

The manufacturer of a provisionally approved drug must require patients to participate in an observational registry. A manufacturer that fails to comply with registry requirements is subject to civil penalties.

A provisionally approved drug must be labeled as such.

If a drug that receives provisional approval status is not brought to market within 180 days of the approval, the approval must be rescinded.

The bill also limits the liability of a manufacturer of a provisionally approved drug with respect to any claim under state law alleging that the drug is unsafe or ineffective.

Private health insurers and federal health care programs shall not deny coverage of a provisionally approved drug on the basis of it being experimental.

The Promising Pathway Act, also known as Bill 117 hr 3761, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to create a pathway for individuals who are currently incarcerated to access education and job training programs in order to help them successfully re-enter society upon their release.

The bill proposes to establish a grant program that would provide funding to correctional facilities to offer education and job training programs to inmates. These programs would focus on developing skills that are in high demand in the workforce, such as computer programming, healthcare, and construction.

Additionally, the Promising Pathway Act aims to incentivize employers to hire individuals who have completed these education and training programs by offering tax credits to businesses that hire formerly incarcerated individuals. This is intended to help reduce recidivism rates and provide opportunities for individuals to build successful careers after serving their time. Overall, the Promising Pathway Act seeks to address the issue of high rates of recidivism by providing individuals with the tools they need to successfully reintegrate into society and build a better future for themselves. It emphasizes the importance of education and job training in helping individuals break the cycle of incarceration and build a promising pathway towards a brighter future.
Congress
117

Number
HR - 3761

Introduced on
2021-06-08

# Amendments
0

Sponsors
+5

Cosponsors
+5

Variations and Revisions

6/8/2021

Status of Legislation

Bill Introduced
Introduced to House
House to Vote
Introduced to Senate
Senate to Vote

Purpose and Summary

Promising Pathway Act

This bill establishes a provisional approval pathway for medicines intended for serious or life-threatening diseases, including illnesses posing a threat of epidemic or pandemic. The period of the provisional approval is for two years and is potentially renewable.

The Food and Drug Administration (FDA) must establish a priority review system to evaluate completed provisional approval applications within 90 days of receipt. A provisional approval application may be approved if the FDA determines that (1) there is substantial evidence of safety for the drug; and (2) there is relevant early evidence of efficacy, based on adequate and well-controlled investigations.

During the COVID-19 (i.e., coronavirus disease 2019) pandemic, or another epidemic or pandemic, the FDA must accept and review various portions of a provisional approval application on a rolling basis.

The manufacturer of a provisionally approved drug must require patients to participate in an observational registry. A manufacturer that fails to comply with registry requirements is subject to civil penalties.

A provisionally approved drug must be labeled as such.

If a drug that receives provisional approval status is not brought to market within 180 days of the approval, the approval must be rescinded.

The bill also limits the liability of a manufacturer of a provisionally approved drug with respect to any claim under state law alleging that the drug is unsafe or ineffective.

Private health insurers and federal health care programs shall not deny coverage of a provisionally approved drug on the basis of it being experimental.

The Promising Pathway Act, also known as Bill 117 hr 3761, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to create a pathway for individuals who are currently incarcerated to access education and job training programs in order to help them successfully re-enter society upon their release.

The bill proposes to establish a grant program that would provide funding to correctional facilities to offer education and job training programs to inmates. These programs would focus on developing skills that are in high demand in the workforce, such as computer programming, healthcare, and construction.

Additionally, the Promising Pathway Act aims to incentivize employers to hire individuals who have completed these education and training programs by offering tax credits to businesses that hire formerly incarcerated individuals. This is intended to help reduce recidivism rates and provide opportunities for individuals to build successful careers after serving their time. Overall, the Promising Pathway Act seeks to address the issue of high rates of recidivism by providing individuals with the tools they need to successfully reintegrate into society and build a better future for themselves. It emphasizes the importance of education and job training in helping individuals break the cycle of incarceration and build a promising pathway towards a brighter future.
Alternative Names
Official Title as IntroducedTo amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited provisional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.

Policy Areas
Health

Potential Impact
Cardiovascular and respiratory health•
Civil actions and liability•
Congressional oversight•
Drug safety, medical device, and laboratory regulation•
Drug therapy•
Emergency medical services and trauma care•
Employee benefits and pensions•
Government information and archives•
Government studies and investigations•
Health care costs and insurance•
Health care coverage and access•
Health information and medical records•
Immunology and vaccination•
Infectious and parasitic diseases•
Licensing and registrations•
Manufacturing•
Medical research•
Medical tests and diagnostic methods•
Prescription drugs•
Scientific communication

Comments

Recent Activity

Latest Summary7/27/2021

Promising Pathway Act

This bill establishes a provisional approval pathway for medicines intended for serious or life-threatening diseases, including illnesses posing a threat of epidemic or pandemic. The period of the provisional a...


Latest Action6/9/2021
Referred to the Subcommittee on Health.